TY - JOUR
T1 - HE3286, an orally bioavailable synthetic analogue of an active DHEA metabolite suppresses spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse
AU - Kosiewicz, Michele M.
AU - Auci, Dominick L.
AU - Fagone, Paolo
AU - Mangano, Katia
AU - Caponnetto, Salvatore
AU - Tucker, Colleen F.
AU - Azeem, Nabeel
AU - White, Steven K.
AU - Frincke, James M.
AU - Reading, Christopher L.
AU - Nicoletti, Ferdinando
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/5/11
Y1 - 2011/5/11
N2 - 5-Androstene-3β,7β,17β-triol (AET) is a naturally occurring anti-inflammatory adrenal steroid that limits acute and chronic inflammation. HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol) is a synthetic derivative of AET with improved pharmaceutical properties and efficacy in some animal models of autoimmunity. Here, daily oral doses of HE3286 led to a suppression of spontaneous autoimmune diabetes in the non-obese diabetic mouse model of type 1 diabetes mellitus when administered either shortly before or after the first incidence of disease onset. Efficacy was associated with reduced insulitis and a suppression of the pathogenic T helper cell type 1 and type 17 phenotypes in peripheral lymphoid organs. These results demonstrate that daily oral treatment with HE3286 administrated relatively late in the destructive autoimmune process led to a suppression of type 1 diabetes mellitus onset and of the pathological inflammatory status, supporting its clinical evaluation in type 1 diabetes mellitus subjects.
AB - 5-Androstene-3β,7β,17β-triol (AET) is a naturally occurring anti-inflammatory adrenal steroid that limits acute and chronic inflammation. HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol) is a synthetic derivative of AET with improved pharmaceutical properties and efficacy in some animal models of autoimmunity. Here, daily oral doses of HE3286 led to a suppression of spontaneous autoimmune diabetes in the non-obese diabetic mouse model of type 1 diabetes mellitus when administered either shortly before or after the first incidence of disease onset. Efficacy was associated with reduced insulitis and a suppression of the pathogenic T helper cell type 1 and type 17 phenotypes in peripheral lymphoid organs. These results demonstrate that daily oral treatment with HE3286 administrated relatively late in the destructive autoimmune process led to a suppression of type 1 diabetes mellitus onset and of the pathological inflammatory status, supporting its clinical evaluation in type 1 diabetes mellitus subjects.
KW - Androstene
KW - Diabetes
KW - IL-17
KW - NOD
KW - Steroid
UR - http://www.scopus.com/inward/record.url?scp=79953791858&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953791858&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2011.02.016
DO - 10.1016/j.ejphar.2011.02.016
M3 - Article
C2 - 21371458
AN - SCOPUS:79953791858
SN - 0014-2999
VL - 658
SP - 257
EP - 262
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2-3
ER -